Serological response to 13-valent pneumococcal conjugate vaccine in children and adolescents with perinatally acquired HIV infection

AIDS

Volumn 28, Issue 14, 2014, Pages 2033-2043

  Bamford, Alasdair ^a   Kelleher, Peter ^b   Lyall, Hermione ^c   Haston, Mitch ^d   Zancolli, Marta ^d   Goldblatt, David ^d   Kampmann, Beate ^a,e  

^a Section of Paediatrics   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e MRC Unit   (Gambia)

Author keywords

HIV; Paediatrics; Pneumococcal vaccines; Serology; Vaccination

Indexed keywords

ANTIRETROVIRUS AGENT; IMMUNOGLOBULIN G; PNEUMOCOCCUS VACCINE; BACTERIUM ANTIBODY; PREVENAR13; VACCINE; VIRUS ANTIBODY;

ADOLESCENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ASSAY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; MALE; OPSONOPHAGOCYTIC ASSAY; PERINATAL PERIOD; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SEROTYPE; VACCINATION; VIRUS DETECTION; VIRUS INHIBITION; VIRUS LOAD; AIDS-RELATED OPPORTUNISTIC INFECTIONS; BLOOD; COMPLICATION; FOLLOW UP; IMMUNOLOGY; PNEUMOCOCCAL INFECTIONS; PRACTICE GUIDELINE; PRESCHOOL CHILD; TIME; TREATMENT OUTCOME; UNITED KINGDOM; YOUNG ADULT;

ADOLESCENT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN G; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PRACTICE GUIDELINES AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; VACCINATION; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84906773452     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000385     Document Type: Article

References (41)

1. Nunes MC, von Gottberg A, de Gouveia L, Cohen C, Kuwanda L, Karstaedt AS, et al. Persistent high burden of invasive pneumococcal disease in South African HIV-infected adults in the era of an antiretroviral treatment program. PLoS One 2011; 6: e27929.
2. Madhi SA, Adrian P, Kuwanda L, Jassat W, Jones S, Little T, et al. Long-Term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and noninfected children in the absence of a booster dose of vaccine. Vaccine 2007; 25: 2451-2457.
3. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N, Vaccine Trialists G. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349: 1341-1348.
4. French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362: 812-822.
5. King JC Jr, Vink PE, Farley JJ, Parks M, Smilie M, Madore D, et al. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and nonhuman immunodeficiency virus-infected children. Pediatr Infect Dis J 1996; 15: 192-196.
6. Madhi SA, Klugman KP, Kuwanda L, Cutland C, Kayhty H, Adrian P. Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination. J Infect Dis 2009; 199: 1168-1176.
7. Thanee C, Pancharoen C, Likitnukul S, Luangwedchakarn V, Umrod P, Phasomsap C, et al. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children. Vaccine 2011; 29: 5886-5891.
8. Costa Ide C, Guilardi F, Kmiliauskis MA, Arslanian C, Baldacci ER. Evaluation of humoral response to heptavalent pneumococcal conjugate vaccine in HIV-infected children. Rev Saude Publica 2008; 42: 844-850.
9. Spoulou VI, Tsoumas DL, Papaevangelou VG, Mostrou GI, Theodoridou MC. Immunogenicity and immunological memory induced by a 7-valent pneumococcal CRM197 conjugate vaccine in symptomatic HIV-1 infected children. Vaccine 2005; 23: 5289-5293.
10. Tarrago D, Casal J, Ruiz-Contreras J, Ramos JT, Rojo P, Snippe H, et al. Assessment of antibody response elicited by a 7-valent pneumococcal conjugate vaccine in pediatric human immunodeficiency virus infection. Clin Diagn Lab Immunol 2005; 12: 165-170.
11. Abzug MJ, Pelton SI, Song LY, Fenton T, Levin MJ, Nachman SA, et al. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2006; 25: 920-929.
12. Abzug MJ, Song LY, Levin MJ, Nachman SA, Borkowsky W, Pelton SI, et al. Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy. Vaccine 2013; 31: 4782-4790.
13. Nunes MC, Madhi SA. Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals. Hum Vaccin Immunother 2012; 8: 161-173.
14. Tobin NH, Aldrovandi GM. Immunology of pediatric HIV infection. Immunol Rev 2013; 254: 143-169.
15. Balmer P, Borrow R, Findlow J, Warrington R, Frankland S, Waight P, et al. Age-stratified prevalences of pneumococcalserotype-specific immunoglobulin G in England and their relationship to the serotype-specific incidence of invasive pneumococcal disease prior to the introduction of the pneumococcal 7-valent conjugate vaccine. Clin Vaccine Immunol 2007; 14: 1442-1450.
16. Mitchell R, Truck J, Pollard AJ. Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6-17 years. Expert Opin Biol Ther 2013; 13: 1451-1465.
17. Rozenbaum MH, van Hoek AJ, Fleming D, Trotter CL, Miller E, Edmunds WJ. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. Br Med J 2012; 345: e6879.
18. Menson EN, Mellado MJ, Bamford A, Castelli G, Duiculescu D, Marczynska M, et al. Guidance on vaccination of HIV-infected children in Europe. HIV Med 2012; 13: 333-336e 331-314.
19. American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23). Pediatrics 2010; 126: 186-190.
20. Soininen A, Pursiainen H, Kilpi T, Kayhty H. Natural development of antibodies to pneumococcal capsular polysaccharides depends on the serotype: association with pneumococcal carriage and acute otitis media in young children. J Infect Dis 2001; 184: 569-576.
21. Ferreira DM, Neill DR, Bangert M, Gritzfeld JF, Green N, Wright AK, et al. Controlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults. Am J Respir Crit Care Med 2013; 187: 855-864.
22. Madhi SA, Petersen K, Madhi A, Wasas A, Klugman KP. Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children. Pediatr Infect Dis J 2000; 19: 1141-1147.
23. Fry AM, Facklam RR, Whitney CG, Plikaytis BD, Schuchat A. Multistate evaluation of invasive pneumococcal diseases in adults with human immunodeficiency virus infection: serotype and antimicrobial resistance patterns in the United States. J Infect Dis 2003; 188: 643-652.
24. Jones N, Huebner R, Khoosal M, Crewe-Brown H, Klugman K. The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population. AIDS 1998; 12: 2177-2184.
25. Kamboj KK, Kirchner HL, Kimmel R, Greenspan NS, Schreiber JR. Significant variation in serotype-specific immunogenicity of the seven-valent Streptococcus pneumoniae capsular polysaccharide-CRM197 conjugate vaccine occurs despite vigorous T cell help induced by the carrier protein. J Infect Dis 2003; 187: 1629-1638.
26. Iwajomo OH, Finn A, Moons P, Nkhata R, Sepako E, Ogunniyi AD, et al. Deteriorating pneumococcal-specific B-cell memory in minimally symptomatic African children with HIV infection. J Infect Dis 2011; 204: 534-543.
27. Pensieroso S, Cagigi A, Palma P, Nilsson A, Capponi C, Freda E, et al. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 verticallyinfected children. Proc Natl Acad Sci U S A 2009; 106: 7939-7944.
28. Ghosh S, Feyen O, Jebran AF, Huck K, Jetzek-Zader M, Bas M, Niehues T. Memory B cell function in HIV-infected childrendecreased memory B cells despite ART. Pediatr Res 2009; 66: 185-190.
29. Jacobsen MC, Thiebaut R, Fisher C, Sefe D, Clapson M, Klein N, Baxendale HE. Pediatric human immunodeficiency virus infection and circulating IgDR memory B cells. J Infect Dis 2008; 198: 481-485.
30. Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol 2009; 9: 235-245.
31. Johannesson TG, Sogaard OS, Tolstrup M, Petersen MS, Bernth-Jensen JM, Ostergaard L, Erikstrup C. The impact of B-cell perturbations on pneumococcal conjugate vaccine response in HIV-infected adults. PLoS One 2012; 7: e42307.
32. van Grevenynghe J, Cubas RA, Noto A, DaFonseca S, He Z, Peretz Y, et al. Loss of memory B cells during chronic HIV infection is driven by Foxo3a-And TRAIL-mediated apoptosis. J Clin Invest 2011; 121: 3877-3888.
33. Hart M, Steel A, Clark SA, Moyle G, Nelson M, Henderson DC, et al. Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease. J Immunol 2007; 178: 8212-8220.
34. D'Orsogna LJ, Krueger RG, McKinnon EJ, French MA. Circulating memory B-cell subpopulations are affected differently by HIV infection and antiretroviral therapy. AIDS 2007; 21: 1747-1752.
35. Titanji K, Chiodi F, Bellocco R, Schepis D, Osorio L, Tassandin C, et al. Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. AIDS 2005; 19: 1947-1955.
36. Siber GR, Chang I, Baker S, Fernsten P, O'Brien KL, Santosham M, et al. Estimating the protective concentration of antipneumococcal capsular polysaccharide antibodies. Vaccine 2007; 25: 3816-3826.
37. Auranen K, Rinta-Kokko H, Goldblatt D, Nohynek H, O'Brien KL, Satzke C, et al. Colonisation endpoints in Streptococcus pneumoniae vaccine trials. Vaccine 2013; 32: 153-158.
38. Cohen AL, Harrison LH, Farley MM, Reingold AL, Hadler J, Schaffner W, et al. Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization. AIDS 2010; 24: 2253-2262.
39. Sutcliffe CG, Moss WJ. Do children infected with HIV receiving HAART need to be revaccinated? Lancet Infect Dis 2010; 10: 630-642.
40. Collins IJ, Judd A, Gibb DM. Immediate antiretroviral therapy in young HIV-infected children: benefits and risks. Curr Opin HIV AIDS 2014; 9: 87-94.
41. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2013. http://apps.who.int/iris/bitstream/10665/ 85321/1/9789241505727-eng.pdf?ua=1. [Accessed May 2014]